Survival analysis of patients with metastatic sarcomatoid renal cell carcinoma and treatment progress
-
摘要: 目的:探究影响转移型肉瘤样肾癌(msRCC)患者预后的危险因素及治疗方案。方法:回顾分析SEER数据库的413例msRCC患者的临床资料。采用Kaplan-Meier生存分析计算总体生存率(OS)及肿瘤特异性生存率(CSS),对随访数据进行COX多因素回归分析,分析因素包括婚姻状态、年龄、种族、性别、肿瘤侧别、Grade分级、Fuhrman核分级、肿瘤大小、区域淋巴结转移、远处转移灶、原发肿瘤的局部浸润、肿瘤原发灶手术方式、区域淋巴结清扫情况、放化疗。结果:研究发现,msRCC患者的5年OS约为3.7%,5年CSS约为4.3%。COX多因素回归发现,年龄＞70岁、区域淋巴结转移、肝转移、肺转移作为影响预后的独立危险因素;而肾切除术(包括根治切除)、化疗则作为预后保护因素。对于存在骨、肝、肺或多发器官转移的msRCC患者,采取减瘤性肾切除术可显著改善预后。结论:msRCC的恶性程度极高,患者预后不良,常规治疗不敏感,研究发现采取减瘤性肾切除术及化疗可改善msRCC患者预后。近年来发现PD-1/PD-L1在sRCC患者存在的高表达特性,未来PD-1/PD-L1抑制剂可能将作为msRCC的一线治疗。Abstract: Objective: To investigate the independent prognostic factors for metastatic sarcomatoid renal cell carcinoma(msRCC) and the progress on treatment. Method: Clinical data from a cohort of 413 msRCC patients were collected from 2010 to 2016 based on the SEER database. Overall survival(OS) and cancer-specific survival(CSS) were calculated using the Kaplan-Meier method. The COX regression model was utilized to analyze factors(including marital status, age, race, sex, laterality, tumor grade, Fuhrman nuclear grade, tumor size, regional lymph node, metastatic disease, tumor invasion, surgery of primary tumor, surgery of regional lymph node, radiotherapy and chemotherapy) influencing patient prognosis. Result: As discovered when analyzing the research data, the five-year OS and five-year CSS were 3.7% and 4.3% for msRCC patients, respectively. Besides, COX regression analysis showed that age＞70 years, regional lymph node metastasis, liver metastasis and lung metastasis were the independent risk factors for survival prognosis, whereas nephrectomy(including radical nephrectomy) and chemotherapy were the protective factors. In addition, cytoreductive nephrectomy was suggested to improve the prognosis for msRCC patients with bone, liver, lung or multiple organ metastases.Conclusion: MsRCC is associated with a high malignant grade and poor patient prognosis, and these patients are often insensitive to routine treatment. Based on our results, the prognosis for msRCC patients can be improved by cytoreductive nephrectomy and chemotherapy. The existing biomarker studies suggest that PD-1/PD-L1 is up-regulated in sRCC, and PD-1/PD-L1 inhibitors may serve as the first-line treatment for msRCC in the future.
-
Key words:
- renal carcinoma /
- prognosis /
- survival analysis /
- COX regression /
- treatment progress
-
-
[1] Shuch B,Pantuck AJ,Pouliot F,et al.Quality of pathological reporting for renal cell cancer:implications for systemic therapy,prognostication and surveillance[J].BJU Int,2011,108(3):343-348.
[2] Amin MB.AJCC Cancer Staging Manual,8th Edition[M].New York:Springer,2017:739-749.
[3] Zhang BY,Thompson RH,Lohse CM,et al.A novel prognostic model for patients with sarcomatoid renal cell carcinoma[J].BJU Int,2015,115(3):405-411.
[4] Alevizakos M,Gaitanidis A,Nasioudis D,et al.Sarcomatoid Renal Cell Carcinoma:Population-Based Study of 879 Patients[J].Clin Genitourin Cancer,2019,17(3):e447-e453.
[5] Farrow GM,Harrison EG,Utz DC.Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults.3[J].Cancer,1968,22:556-563.
[6] Delahunt B,Cheville JC,Martignoni G,et al.The International Society of Urological Pathology(ISUP)grading system for renal cell carcinoma and other prognostic parameters[J].Am J Surg Pathol,2013,37(10):1490-504.
[7] Lebacle C,Pooli A,Bessede T,et al.Epidemiology,biology and treatment of sarcomatoid RCC:current state of the art[J].World J Urol,2019,37(1):115-123.
[8] Cheville JC,Lohse CM,Zincke H,et al.Sarcomatoid renal cell carcinoma:an examination of underlying histologic subtype and an analysis of associations with patient outcome[J].Am J Surg Pathol,2004,28(4):435-441.
[9] Smith SC,Trpkov K,Chen YB,et al.Tubulocystic carcinoma of the kidney with poorly differentiated foci:a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma[J].Am J Surg Pathol,2016,40(11):1457-1472.
[10] Williamson SR,Eble JN,Amin MB,et al.Succinate dehydrogenase-deficient renal cell carcinoma:detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma[J].Mod Pathol,2015,28(1):80-94.
[11] Mouallem NE,Smith SC,Paul AK.Sarcomatoid renal cell carcinoma:Biology and treatment advances[J].Urol Oncol,2018,36(6):265-271.
[12] Bi M,Zhao S,Said J W,et al.Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma[J].Proc Natl Acad Sci U S A,2016,113(8):2170-2175.
[13] Malouf GG,Ali SM,Wang K,et al.Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations[J].Eur Urol,2016,70(2):348-357.
[14] Molina AM,Tickoo SK,Ishill N,et al.Sarcomatoid-variant renal cell carcinoma:treatment outcome and survival in advanced disease[J].Am J Clin Oncol,2011,34(5):454-459.
[15] Merrill MM,Wood CG,Tannir NM,et al.Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation:Natural history and outcomes after surgical resection with curative intent[J].Urol Oncol,2015,33(4):166.e21-9.
[16] Heng DY,Wells JC,Rini BI,et al.Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma:results from the International Metastatic Renal Cell Carcinoma Database Consortium[J].Eur Urol,2014,66(4):704-710.
[17] Keskin SK,Msaouel P,Hess KR,et al.Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies:Comparison between the Cytokine and Targeted Therapy Eras[J].J Urol,2017,198(3):530-537.
[18] Thomas AZ,Adibi M,Slack RS,et al.The role of metastasectomy in patients with renal cell carcinoma with sarcomatoid dedifferentiation:a matched controlled analysis[J].J Urol,2016,196(3):678-684.
[19] Park I,Cho YM,Lee JL,et al.Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component[J].J Cancer Res Clin Oncol,2013,139(5):817-827.
[20] Haas NB,Lin X,Manola J,et al.A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features:ECOG 8802[J].Med Oncol,2012,29(2):761-767.
[21] Escudier B,Droz JP,Rolland F,et al.Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma:a phase II study of the Genitourinary Group of the French Federation of Cancer Centers[J].J Urol,2002,168(3):959-961.
[22] Maiti A,Nemati-Shafaee M,Msaouel P,et al.Phase 2 Trial of Capecitabine,Gemcitabine,and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma[J].Clin Genitourin Cancer,2017,7673(17):30238.
[23] Kwak C,Park YH,Jeong CW,et al.Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma[J].J Surg Oncol,2007,95(4):317-323.
[24] Golshayan AR,George S,Heng DY,et al.Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy[J].J Clin Oncol,2009,27(2):235-241.
[25] Pitt JM,Vétizou M,Daillère R,et al.Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer:Tumor-Intrinsic and-Extrinsic Factors[J].Immunity,2016,44(6):1255-1269.
[26] Herbst RS,Soria JC,Kowanetz M,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature,2014,515(7528):563-567.
[27] Thompson RH,Dong H,Lohse CM,et al.PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma[J].Clin Cancer Res,2007,13(6):1757-1761.
[28] Rini BI,Powles T,Atkins MB,et al.IMmotion151 Study Group.Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma(IMmotion151):a multicentre,open-label,phase 3,randomised controlled trial[J].Lancet,2019,393(10189):2404-2415.
[29] Motzer RJ,Tannir NM,McDermott DF,et al.Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma[J].N Engl J Med,2018,378(14):1277-1290.
-
计量
- 文章访问数: 661
- PDF下载数: 504
- 施引文献: 0
下载: